Covid-19: what are the four new vaccines planned for this fall?

Covid-19: what are the four new vaccines planned for this fall?

The peak of the 7th wave has largely passed, we are in the midst of the August summer depression … Everything is in place for the vaccination rate against Covid-19 to mark the time. Only 55,000 doses are given each day, the vast majority of second booster doses, which is half as many as in mid-July.

The pace could resume at the beginning of the school year. The arrival of a probable eighth wave could encourage a number of villagers to reach out to hand once again. Additionally, the High Authority for Health could recommend a new booster dose for frail people, or even extend the target to adults without comorbidities. Everything will depend in particular on the vaccines available, potentially more effective – especially against infections – than those with messenger RNA (Pfizer / BioNTech or Moderna) currently used. Four new products are planned for September or October by the Ministry of Health, the latter indicated on July 20. Here they are.

Ipra

  • Technology: Recombinant protein vaccine.
  • Variants from which it is composed: Alpha and Beta.
  • Efficiency: In a press release published on July 19, the Spanish company assures that “an increase in neutralizing antibodies against Omicron BA.2, BA.4 and BA.5 was observed 14 days after the administration of the vaccine as a booster dose in the participants. previously vaccinated “with two doses of Pfizer / BioNTech or Moderna vaccine. We do not yet have more precise rates of efficacy, neither against infections nor against severe forms.
  • Advancement: the European Commission announced on Tuesday that it has signed an agreement that allows it to acquire up to 250,000 doses of the vaccine developed by the Spanish company. But it will first need to be authorized by the European Medicines Agency (EMA). The Hipra vaccine is still subject to a continuous review procedure, i.e. the available data are analyzed in real time, without waiting for the filing of a marketing authorization.

Sanofì

  • Technology: Recombinant protein vaccine.
  • Variants from which it is composed: Original virus strain and Beta variant.
  • Efficiency: In a press release published on June 24, the French group states that a booster dose of their vaccine was found to be 72% effective (45.8 to 86.6% confidence interval) against symptomatic forms with the Omicron variant. . In people who have already had Covid and therefore also benefit from the so-called “natural” immunity, this protection has risen to 93.2% (confidence interval between 73.2% and 99.2%). This study did not focus on the BA.5 sub-lineage of the Omicron variant, which is now the majority in France, but the efficacy of current vaccines appears similar against each member of the Omicron “family”.
  • Advancement: While its vaccine (developed with UK manufacturer GSK) has been under constant review since July 2021, more than a year ago Sanofi submitted a marketing authorization application to the EMA last March.

Pfizer / BioNTech adapted to Omicron

  • Technology: Messenger RNA vaccine.
  • Variants from which it is composed: Original virus strain and Omicron variant (BA.1 initially).
  • Efficiency: This so-called “adapted” vaccine produced “significantly higher neutralizing antibody responses against Omicron BA.1” than the one currently used, according to a June 25 press release from Pfizer. On the other hand, the impact is less against BA.5 than against BA.1, with three times lower antibody titers. “This reduces the duration of protection compared to what it would be if the virus had not evolved any more,” recently deciphered medical biologist Claude-Alexandre Gustave. The US Federal Drug Agency (FDA) has also asked RNA messenger manufacturers to also develop versions adapted to BA.5 and its “little brother” BA.4 in order to improve performance.
  • Advancement: Pfizer and its partner BioNTech announced on July 19 that they had submitted their data to the EMA. Three days later, he announced that he had begun his evaluation.

Modern adapted to Omicron

  • Technology: Messenger RNA vaccine.
  • Variants from which it is composed: Original virus strain and variant Omicron BA.1 or BA.4 / 5.
  • Efficiency: Among participants who had never had Covid, the Omicron-adapted BA.1 vaccine “resulted in significantly higher neutralizing titers against BA.4 / 5 than (that) currently authorized,” Moderna teases in a published press release. on July 11. After a month, these were almost double. Furthermore, this new vaccine “is generally well tolerated”, with no more side effects than the current one. As for the other bivalent vaccine candidate, based on the original virus strain and this time on the Omicron BA.5 variant, data are not yet available.
  • Advancement: Like Pfizer / BioNTech, Moderna’s adapted vaccines have been officially evaluated by the EMA since July 22.

#Covid19 #vaccines #planned #fall